Adaptive biotechnologies stock.

In summary, Adaptive Biotechnologies Corp (ADPT) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Adaptive biotechnologies stock. Things To Know About Adaptive biotechnologies stock.

Nov 29, 2023 · Stock analysis for Adaptive Biotechnologies Corp (ADPT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Before we jump into Adaptive Biotechnologies Corp’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background. Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on using the biology of the adaptive immune system to …In addition, Adaptive Biotechnologies Corporation has a VGM Score of F (this is a weighted average of the individual Style Scores which allow you to focus on the stocks that best fit your personal ...Adaptive Biotechnologies ( ADPT -9.24%) is a biotech-adjacent stock that peaked in January and then fell hard. It's down 61% from its high-water mark, but the average analyst on Wall Street thinks ...5.20% of Adaptive Biotechnologies stock is owned by insiders. Learn more on ADPT's insider holdings. Which Adaptive Biotechnologies insiders have been selling company stock? The following insiders have sold ADPT shares in the last 24 months: Chad M Cohen ($300,000.00), ...

Get the latest Adaptive Biotechnologies Corporation ADPT detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.

Adaptive Biotechnologies Corp does not have a meaningful P/E due to negative earnings over the last 12 trailing months. Adaptive Biotechnologies Corp’s trailing 12-month revenue is $189.6 million with a -100.7% profit margin. Year-over-year quarterly sales growth most recently was 11.9%.

View Adaptive Biotechnologies Corporation ADPT investment & stock information. Get the latest Adaptive Biotechnologies Corporation ADPT detailed stock ...Wood has been adding to Adaptive Biotechnologies -- with a market cap barely above $1 billion -- in recent days. Homing in on immune-system genetic sequencing technology, Adaptive hasn't had a ...Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 2023 Earnings Call Transcript November 9, 2023 Adaptive Biotechnologies Corporation misses on earnings …As of March 24, 2023, 4:00 PM CST, Adaptive Biotechnologies Corp’s stock price was $8.43. Adaptive Biotechnologies Corp is up 7.53% from its previous closing price of $7.84. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $7.79 and $8.24. Currently, there are 143.06 million shares of Adaptive ...

April 18, 2023 at 12:10 PM · 3 min read. You may think that with a price-to-sales (or "P/S") ratio of 6.4x Adaptive Biotechnologies Corporation ( NASDAQ:ADPT) is a stock to potentially avoid ...

6. Adaptive Biotechnologies -- $6 a share. Adaptive Biotechnologies ( ADPT 6.95%) may get cheaper in the short-term, but this biotech has an exciting platform that should unlock a lot of value ...

SEATTLE, Dec. 10, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced new data demonstrating the strengths of Adaptive’s next-generation ...Track Adaptive Biotechnologies Corp (ADPT) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsAdaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023. SEATTLE, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose …Analyst Recommendations on Adaptive Biotechnologies Corporation. Morgan Stanley Cuts Adaptive Biotechnologies' Price Target to $10 From $13, Keeps Equalweight Rating. Oct. 24. MT. BofA Securities Trims Price Target on Adaptive Biotechnologies to $9 From $11, Maintains Buy Rating. Oct. 20. Adaptive Biotechnologies (ADPT) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the ...Apr 12, 2023. Listen to this article 3 min. Mark Adams, chief operating officer of Adaptive Biotechnologies Corp. (Nasdaq: ADPT), is moving on from the Seattle-based biotech company. In a Tuesday ...Adaptive Biotechnologies Corp does not have a meaningful P/E due to negative earnings over the last 12 trailing months. Adaptive Biotechnologies Corp’s trailing 12-month revenue is $189.6 million with a -100.7% profit margin. Year-over-year quarterly sales growth most recently was 11.9%.

SEATTLE, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the launch of its clonoSEQ ® Assay to detect minimal residual disease ...Sep 26, 2023 · Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the adaptive immune system to facilitate the diagnosis and treatment of disease. Its clinical diagnostic ... Apr 25, 2023 · Adaptive Biotechnologies Corp is down 9.82% from its previous closing price of $8.25. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $8.20 and $8.61. Currently, there are 143.06 million shares of Adaptive Biotechnologies Corp stock available for purchase. Unfortunately, Adaptive Biotechnologies Corp’s P ... Adaptive Biotechnologies‘ stock rose 6 percent to $30 per share in after-hours trading on Tuesday after the company reported higher revenues and narrower losses than expected for its third ...Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 0% and 7.57%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Aug 2, 2023 · SEATTLE, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the ...

Get Adaptive Biotechnologies Corp (ADPT.OQ) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investmentsAbout Adaptive Biotechnologies Stock. Adaptive Biotechnologies aims to help scientists look at the immune system in a new way, with a combination of DNA sequencing and high-powered computation, to analyze the DNA sequences that make up the immune system. Unlike other cell types, which operate on a fixed set of code from the human …If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...Description. Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to …Piper Sandler has a $15 target price for Adaptive Biotechnologies stock. The consensus target is $12.29, and shares closed on Friday at $7.46, which was up almost 6% for the day.Interested individuals can access further details through the hyperlink provided by Adaptive Biotechnologies. Overall insider trading activity for Adaptive Biotechnologies has been noteworthy, with insiders recently selling 242,961 shares of the company’s stock. These transactions have amounted to a total value of $1,967,763.

Information on stock, financials, earnings, subsidiaries, investors, and executives for Adaptive Biotechnologies. Use the PitchBook Platform to explore the ...

How much a company is worth is typically represented by its market capitalization, or the current stock price multiplied by the number of shares outstanding.

The latest closing stock price for Adaptive Biotechnologies as of November 24, 2023 is 4.37. The all-time high Adaptive Biotechnologies stock closing price was 67.74 on …Get the latest Adaptive Biotechnologies Corporation (ADPT) stock quote, history, news and other vital information to help you with your stock trading and investing. See the performance outlook, earnings date, dividend yield, research reports and more for ADPT on NasdaqGS.Jun 30, 2023 · Second Quarter 2023 Financial Results. Revenue was $48.9 million for the quarter ended June 30, 2023, representing a 12% increase from the second quarter in the prior year. Immune Medicine revenue was $23.0 million for the quarter, representing a 3% increase from the second quarter in the prior year. Nov 29, 2023 · In the past three months, Adaptive Biotechnologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,070.00 in company stock. Percentage Held by Insiders. Only 5.20% of the stock of Adaptive Biotechnologies is held by insiders. Percentage Held by Institutions SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the ...Adaptive Biotechnologies Corp. ( NASDAQ: ADPT) stock is down over 72% in the previous 52-weeks and 58.5% YTD. Since its inception, the company has been a loss-maker. Still, the revenues have been ...The upgrade of Adaptive Biotechnologies to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the ...ADPT - Adaptive Biotechnologies Corp Stock quote - CNNMoney.com Adaptive Biotechnologies Corp (NASDAQ:ADPT) 4.64 Delayed Data As of Nov 29 +0.27 / …Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 2023 Earnings Call Transcript November 9, 2023 Adaptive Biotechnologies Corporation misses on earnings expectations. Reported EPS is $-0.35 ...This presentation has been prepared by Adaptive Biotechnologies Corporation (“we,” “us,” “our,” “Adaptive” or the “Company”) and is made for informational purposes only. The information set forth herein does not purport to be complete or …Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 2023 Earnings Call Transcript November 9, 2023 Adaptive Biotechnologies Corporation misses on earnings expectations. Reported EPS is $-0.35 ...Get the latest Adaptive Biotechnologies Corporation ADPT detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.

Andris Zoltners ADPT stock SEC Form 4 insiders trading. Andris has made over 2 trades of the Adaptive Biotechnologies stock since 2020, according to the Form 4 filled with the SEC. Most recently Andris sold 345,000 units of ADPT stock worth $9,142,500 on 28 January 2020.. The largest trade Andris's ever made was selling 345,000 units of …Jul 21, 2023 · Adaptive Biotechnologies Corp’s Stock Price as of Market Close. As of July 21, 2023, 4:00 PM CST, Adaptive Biotechnologies Corp’s stock price was $8.08. Adaptive Biotechnologies Corp is up 4.94% from its previous closing price of $7.70. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $7.60 and $7.79. Track Adaptive Biotechnologies Corp (ADPT) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsInstagram:https://instagram. nasdaq aurbest pre ipo investment platformwhere to buy xdc coinfuture fintech Employment: Adaptive Biotechnologies. Stock and Other Ownership Interests: Adaptive Biotechnologies. Maneesh Tandon. Employment: Roche (I) Stock and Other Ownership Interests: Roche Pharma AG. Anna-Maria Fink. Research Funding: Celgene/Bristol Myers Squibb (Inst), AstraZeneca (Inst)What percentage of Adaptive Biotechnologies stock is owned by insiders? 5.20% of Adaptive Biotechnologies stock is owned by insiders. Learn more on ADPT's insider holdings. buffalo head nickels worth moneystock price aep Adaptive Biotechnologies ( NASDAQ: ADPT) stock fell ~10% on Tuesday after the company said it is terminating the services of its Chief Operating Officer Mark Adams by May. The Seattle-based life ...Nov 30, 2023 · Valuation metrics show that Adaptive Biotechnologies Corporation may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth ... jnj credo Stock analysis for Adaptive Biotechnologies Corp (ADPT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Piper Sandler has a $15 target price on Adaptive Biotechnologies stock. The consensus target is $12.29, and shares last traded on Friday at $8.39. ALSO READ: 5 Warren Buffett Dividend Stocks to ...